Zura Bio (NASDAQ:ZURA) Trading Down 1.5% – Here’s What Happened

Zura Bio Limited (NASDAQ:ZURA) was down 1.5% during trading on Wednesday . The stock traded as low as $5.07 and last traded at $5.24. Approximately 526,269 shares traded hands during mid-day trading, a decline of 0% from the average daily volume of 526,941 shares. The stock had previously closed at $5.32.

Analyst Ratings Changes

ZURA has been the subject of several recent research reports. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Price Performance

The firm has a market capitalization of $340.70 million, a P/E ratio of -8.06 and a beta of 0.24. The business has a 50 day moving average price of $4.00 and a 200 day moving average price of $2.74.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). As a group, equities analysts expect that Zura Bio Limited will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Scientech Research LLC acquired a new position in shares of Zura Bio in the 3rd quarter worth approximately $45,000. Forefront Wealth Partners LLC acquired a new position in Zura Bio in the third quarter valued at $93,000. Squarepoint Ops LLC bought a new position in shares of Zura Bio in the 3rd quarter worth about $109,000. Qube Research & Technologies Ltd acquired a new position in shares of Zura Bio in the 3rd quarter valued at about $138,000. Finally, Savant Capital LLC boosted its position in shares of Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after purchasing an additional 21,249 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.